Dual-Target Nanobody Innovation Against TNFRSF1B and TNFRSF9 for Colorectal Cancer Immunotherapy

VHH-P422 is a fully humanized nanobody-based construct designed to target both TNF receptor superfamily member 1B (TNFRSF1B) and TNF receptor superfamily member 9 (TNFRSF9). Currently under Biological Testing, VHH-P422 combines the specificity of a monoclonal IgG4 kappa antibody and a single-domain antibody to enable dual modulation of critical immune pathways in the tumor microenvironment. This approach holds significant therapeutic promise for the treatment of colorectal cancer, a disease with substantial unmet needs. The innovative bispecific architecture represents a new strategy in leveraging immune system engagement for oncology applications.

Licensing Opportunity

VHH-P422 is available for out-licensing opportunities. We welcome inquiries from partners interested in collaborative development, clinical advancement, or strategic alliances to maximize its application in colorectal cancer immunotherapy.

Development Phase

Modality

VHH-P422 is a bispecific antibody fusion construct that uniquely integrates a human monoclonal IgG4 kappa antibody targeting TNFRSF9, together with a single-domain antibody directed against TNFRSF1B, linked via (G4S)3 linkers at each heavy chain N-terminus. Produced in Chinese hamster ovary cells, this nanobody-enabled construct leverages the inherent stability, small size, and superior tissue penetration of single-domain antibodies. These properties facilitate efficient tumor targeting and immune modulation, enhancing access to the tumor microenvironment typical of colorectal cancer. The tailored design provides versatile engagement of two crucial immune modulators, offering advantages over conventional antibody modalities in terms of biodistribution, manufacturability, and therapeutic potential.

Target

TNFRSF1B and TNFRSF9 are pivotal members of the tumor necrosis factor receptor superfamily with critical immunoregulatory functions. TNFRSF1B is primarily involved in mediating inflammatory and immune responses, with expression seen in T cells, regulatory T cells, and certain tumor cells. TNFRSF9 acts as a co-stimulatory molecule and is predominantly expressed on activated T cells and natural killer cells. Both TNFRSF1B and TNFRSF9 have been shown to influence tumor progression, immune cell infiltration, and antitumor immunity in colorectal cancer. Targeting TNFRSF1B and TNFRSF9 addresses key immunosuppressive mechanisms within the tumor microenvironment and enhances antitumor immune responses. VHH-P422’s simultaneous engagement of TNFRSF1B and TNFRSF9 offers a strategic advantage by orchestrating dual immune activation, positioning it as a highly differentiated asset in cancer immunotherapy.

Mechanism of Action

VHH-P422 employs a dual mechanism of action by simultaneously engaging TNFRSF1B and TNFRSF9. Through agonistic and modulatory interactions, VHH-P422 influences downstream signal transduction in immune effector cells. The anti-TNFRSF1B domain stimulates regulatory signaling pathways, while the anti-TNFRSF9 component promotes immune co-stimulation and cell-mediated cytotoxicity, resulting in enhanced antitumor immune activation. The bispecific nanobody construct enables precise spatial and temporal control of immune signaling cascades. This modular design underscores the broader potential of the nanobody platform to support next-generation modalities such as antibody-drug conjugates, bispecifics, or multi-specific immune-oncology therapeutics, expanding its utility beyond current applications.

Colorectal Cancer

Colorectal cancer is among the most common malignancies worldwide, with its incidence significantly impacting global cancer morbidity and mortality. The disease is characterized by malignant transformation in the colon or rectum, frequently associated with genetic, dietary, and environmental risk factors. Standard-of-care approaches primarily include surgical resection, chemotherapy, radiation therapy, and, increasingly, biologic and targeted strategies. Despite these options, a substantial proportion of patients with advanced or metastatic disease experience limited survival benefits, frequent relapses, or develop resistance to standard treatments. The current clinical landscape is driven by an urgent demand for therapies that improve long-term outcomes and address underlying immune evasion in colorectal cancer. VHH-P422, through innovative targeting of TNFRSF1B and TNFRSF9, has the potential to transform the therapeutic paradigm by leveraging dual immune modulation to overcome resistance and enhance durable antitumor responses.